wouldn’t over - interpret the results, you’re comparing 14 patients here vs a study 30x the size, it only takes one to go the other way and with such a small sample the % response won’t look so good. Best we can say is it’s met its objective of finding a dose to take into the next phase and initial response rates are ok.
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer, page-21
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.8¢ |
Change
-0.012(12.0%) |
Mkt cap ! $24.13M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 8.6¢ | $614.5K | 5.826M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 122997 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.4¢ | 11000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| ATX (ASX) Chart |